⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Figure S4 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia

Vi Lam Carly Roleder Tingting Liu Nur Bruss Scott Best Xiaoguang Wang Tycel Phillips Geoffrey Shouse Allison Berger Lapo Alinari Lili Wang Tanya Siddiqi Nathan D. Pennock Alexey V. Danilov

View at Publisher

Ask AI

Bookmark

Share

Abstract

Figure S4 shows 1x104 A20 lymphoma cells were treated with the indicated doses of TAK-981 for 48 hours.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lam et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db643587523790 https://doi.org/10.1158/1535-7163.27036325

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S1 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia2024
2Figure S2 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia2024
3Table S1 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia2024
4Table S1 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia2024
5Figure S3 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia2024

Table S2 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia2024
Table S2 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia2024
Data from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia2024